نتایج جستجو برای: overall survival

تعداد نتایج: 729668  

Journal: :iranian journal of blood and cancer 0
farhad shahi department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) marziye ghalamkari internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) seyed reza safayi department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) mehrzad mirzania department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) mahdi khatuni internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) faeze almasi internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

background:  allogeneic hematopoietic stem cell transplantation (allo-hsct) is used as treatment of choice for patients with acute myeloid leukemia (aml). we aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-m3 aml who underwent allogenic hsct. methods: this is a cross sectional retrospective study. demographic data and study of variables such as age, sex,...

Background:  Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...

Journal: :Archives of Clinical and Experimental Surgery (ACES) 2017

Journal: :International Journal of Radiation Oncology*Biology*Physics 2016

Journal: :Journal of the American College of Surgeons 2017

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید